KAMADA LTD (KMDA)
About KAMADA LTD
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $413.6M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $413.6M
- Dividend yield
- 3.54%
- Shares outstanding
- 58.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 31, 2013
Kamada Ltd (KMDA) Stock Price
- Trading 24% below its 52-week high.
- Pays a dividend yielding about 3.54% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review KAMADA LTD.
Write a review
News about KAMADA LTD
News & sentiment via Polygon.io
Kamada Ltd: frequently asked questions
Is Kamada Ltd an American company?
Kamada Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Kamada Ltd publicly traded?
Yes — Kamada Ltd is a publicly traded company. Its stock trades under the ticker symbol KMDA on the NASDAQ.
What does Kamada Ltd do?
Kamada Ltd is an American Pharmaceuticals company in the Health & Beauty sector.
When was Kamada Ltd founded?
Kamada Ltd was founded in 1990.
